Cours suspendu

Communiqués Ventyx Biosciences, Inc.

Actions

VTYX

US92332V1070

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 03/03/2026			Varia. 5j.	Varia. 1 janv.
14,00 ^USD	+0,14%		-.--%	+55,04%

04/03	Eli Lilly finalise l'acquisition de Ventyx Biosciences pour environ 1 milliard de dollars	CI
04/03	Ventyx Biosciences, Inc. annonce des changements au sein de sa direction	CI

Communiqués

05/02	Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX	BU
26/01	Halper Sadeh LLC Encourages NATH, VTYX, SKYT Shareholders to Contact the Firm to Discuss Their Rights	PR
13/01	Halper Sadeh LLC Encourages VTYX, SNCY, EKSO Shareholders to Contact the Firm to Discuss Their Rights	PR
12/01	Halper Sadeh LLC Encourages VTYX, FONR, SNCY, FFIC Shareholders to Contact the Firm to Discuss Their Rights	PR
08/01	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)	NE
07/01	Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases	PR
02/12	Ventyx Provides Clinical and Corporate Updates	GL
01/12	Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference	GL
17/11	Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London	GL
06/11	Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress	AQ
22/10/25	Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors	GL
22/10/25	Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors	AQ
27/08/25	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences	AQ
07/08/25	Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress	AQ
17/06/25	Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease	AQ
28/05/25	Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference	AQ
08/05/25	Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress	AQ
01/04/25	Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists	AQ
27/02/25	Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress	AQ
18/02/25	Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025	AQ
05/02/25	Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference	AQ
14/01/25	Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio	AQ
12/11/24	Ventyx Biosciences to Participate in Three Upcoming Investor Conferences	AQ
08/11/24	Ventyx Biosciences : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
07/11/24	Ventyx Biosciences : Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress Form 8 K	PU